Complement-coagulation cross-talk: A potential mediator of the physiological activation of complement by low pH

Frontiers in Immunology

Volumn 6, Issue MAY, 2015, Pages

  Kenawy, Hany Ibrahim ^a   Boral, Ismet ^b   Bevington, Alan ^b  

^a MANSOURA UNIVERSITY   (Egypt)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Alternative pathway; Classical pathway; Coagulation; Complement; Contact system; Lectin pathway; PH

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; C REACTIVE PROTEIN; COMPLEMENT; COMPLEMENT COMPONENT C1R; COMPLEMENT COMPONENT C1S; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C4B; COMPLEMENT COMPONENT C5B; COMPLEMENT COMPONENT C6; ENZYME PRECURSOR; FICOLIN; HIGH MOLECULAR WEIGHT KININOGEN; LIPOPOLYSACCHARIDE; MANNAN BINDING LECTIN ASSOCIATED SERINE PROTEINASE; MANNAN BINDING LECTIN ASSOCIATED SERINE PROTEINASE 1; MANNAN BINDING LECTIN ASSOCIATED SERINE PROTEINASE 2; MANNAN BINDING LECTIN ASSOCIATED SERINE PROTEINASE 3; MANNOSE BINDING LECTIN; MYELIN; PNEUMOLYSIN; PREKALLIKREIN; PROPERDIN; THROMBOPLASTIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS PROTEIN;

ALKALINIZATION; BLOOD CLOTTING; BLOOD VESSEL INJURY; BODY FLUID; CHRONIC KIDNEY DISEASE; COMPLEMENT ACTIVATION; EXTRACELLULAR FLUID; HOMEOSTASIS; HUMAN; INFLAMMATION; INNATE IMMUNITY; METABOLIC ACIDOSIS; NONHUMAN; PATHOPHYSIOLOGY; PH; RENAL TUBULAR FLUID; REVIEW; THROMBOSIS; TISSUE REGENERATION; URINE;

EID: 84934292297     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00215     Document Type: Review

References (119)

1. Hammer CH, Hansch G, Gresham HD, Shin ML. Activation of the fifth and sixth components of the human complement system: C6-dependent cleavage of C5 in acid and the formation of a bimolecular lytic complex, C5b,6a. J Immunol (1983) 131(2):892-8.
2. Fishelson Z, Horstmann RD, Muller-Eberhard HJ. Regulation of the alternative pathway of complement by pH. J Immunol (1987) 138(10):3392-5.
3. Miyazawa K, Inoue K. Complement activation induced by human C-reactive protein in mildly acidic conditions. J Immunol (1990) 145(2):650-4.
4. Emeis M, Sonntag J, Willam C, Strauss E, Walka MM, Obladen M. Acidosis activates complement system in vitro. Mediators Inflamm (1998) 7(6):417-20.
5. Sonntag J, Emeis M, Strauss E, Obladen M. In vitro activation of complement and contact system by lactic acidosis. Mediators Inflamm (1998) 7(1):49-51.
6. Sonntag J, Wagner MH, Strauss E, Obladen M. Complement and contact activation in term neonates after fetal acidosis. Arch Dis Child Fetal Neonatal Ed (1998) 78(2):F125-8. doi:10.1136/fn.78.2.F125
7. Peake PW, Pussell BA, Mackinnon B, Charlesworth JA. The effect of pH and nucleophiles on complement activation by human proximal tubular epithelial cells. Nephrol Dial Transplant (2002) 17(5):745-52. doi:10.1093/ndt/17.5.745
8. Menkin V. The role of hydrogen ion concentration and the cytology of an exudate. In: Menkin V, editor. Biochemical Mechanisms in Inflammation. Springfield, IL: Charles C Thomas (1956). p. 66-103.
9. Rotstein OD, Nasmith PE, Grinstein S. The Bacteroides by-product succinic acid inhibits neutrophil respiratory burst by reducing intracellular pH. Infect Immun (1987) 55(4):864-70.
10. Grinstein S, Swallow CJ, Rotstein OD. Regulation of cytoplasmic pH in phagocytic cell function and dysfunction. Clin Biochem (1991) 24(3):241-7. doi:10.1016/0009-9120(91)80014-T
11. 2 concentration in accessible structures of the rat renal cortex. J Clin Invest (1979) 64(2):476-82. doi:10.1172/JCI109485
12. DuBose TD Jr, Pucacco LR, Seldin DW, Carter NW, Kokko JP. Microelectrode determination of pH and PCO2 in rat proximal tubule after benzolamide: evidence for hydrogen ion secretion. Kidney Int (1979) 15(6):624-9. doi:10.1038/ki.1979.82
13. DuBose TD Jr, Pucacco LR, Carter NW. Determination of disequilibrium pH in the rat kidney in vivo: evidence of hydrogen secretion. Am J Physiol (1981) 240(2):F138-46.
14. Karlmark B, Jaeger P, Giebisch G. Luminal buffer transport in rat cortical tubule: relationship to potassium metabolism. Am J Physiol (1983) 245(5 Pt 1):F584-92.
15. Buerkert J, Martin D, Trigg D. Segmental analysis of the renal tubule in buffer production and net acid formation. Am J Physiol (1983) 244(4):F442-54.
16. Buerkert J, Martin D, Trigg D, Simon E. Effect of reduced renal mass on ammonium handling and net acid formation by the superficial and juxtamedullary nephron of the rat. Evidence for impaired reentrapment rather than decreased production of ammonium in the acidosis of uremia. J Clin Invest (1983) 71(6):1661-75. doi:10.1172/JCI110921
17. Winaver J, Walker KA, Kunau RT Jr. Effect of acute hypercapnia on renal and proximal tubular total carbon dioxide reabsorption in the acetazolamide-treated rat. J Clin Invest (1986) 77(2):465-73. doi:10.1172/JCI112325
18. Brunskill NJ. Albumin signals the coming of age of proteinuric nephropathy. J Am Soc Nephrol (2004) 15(2):504-5. doi:10.1097/01.ASN.0000112912.40303.81
19. Baines RJ, Brunskill NJ. The molecular interactions between filtered proteins and proximal tubular cells in proteinuria. Nephron Exp Nephrol (2008) 110(2):e67-71. doi:10.1159/000161982
20. Dixon R, Brunskill NJ. Activation of mitogenic pathways by albumin in kidney proximal tubule epithelial cells: implications for the pathophysiology of proteinuric states. J Am Soc Nephrol (1999) 10(7):1487-97.
21. Brown KM, Sacks SH, Sheerin NS. Mechanisms of disease: the complement system in renal injury-new ways of looking at an old foe. Nat Clin Pract Nephrol (2007) 3(5):277-86. doi:10.1038/ncpneph0465
22. Sheerin NS, Risley P, Abe K, Tang Z, Wong W, Lin T, et al. Synthesis of complement protein C3 in the kidney is an important mediator of local tissue injury. FASEB J (2008) 22(4):1065-72. doi:10.1096/fj.07-8719com
23. Morita Y, Ikeguchi H, Nakamura J, Hotta N, Yuzawa Y, Matsuo S. Complement activation products in the urine from proteinuric patients. J Am Soc Nephrol (2000) 11(4):700-7.
24. de Brito-Ashurst I, Varagunam M, FAU Raftery MJ, Raftery MJ, Yaqoob MM. Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol (2009) 20(9):2075-84. doi:10.1681/ASN.2008111205
25. Abbate M, Zoja C, Corna D, Rottoli D, Zanchi C, Azzollini N, et al. Complement-mediated dysfunction of glomerular filtration barrier accelerates progressive renal injury. J Am Soc Nephrol (2008) 19(6):1158-67. doi:10.1681/ASN.2007060686
26. Nath KA, Hostetter MK, Hostetter TH. Pathophysiology of chronic tubulo-interstitial disease in rats. Interactions of dietary acid load, ammonia, and complement component C3. J Clin Invest (1985) 76(2):667-75. doi:10.1172/JCI112020
27. Gaarkeuken H, Siezenga MA, Zuidwijk K, van Kooten C, Rabelink TJ, Daha MR, et al. Complement activation by tubular cells is mediated by properdin binding. Am J Physiol Renal Physiol (2008) 295(5):F1397-403. doi:10.1152/ajprenal.90313.2008
28. Clark A, Weymann A, Hartman E, Turmelle Y, Carroll M, Thurman JM, et al. Evidence for non-traditional activation of complement factor C3 during murine liver regeneration. Mol Immunol (2008) 45(11):3125-32. doi:10.1016/j.molimm.2008.03.008
29. Pickering MC, Walport MJ. Links between complement abnormalities and systemic lupus erythematosus. Rheumatology (Oxford) (2000) 39(2):133-41. doi:10.1093/rheumatology/39.2.133
30. Alchi B, Jayne D. Membranoproliferative glomerulonephritis. Pediatr Nephrol (2010) 25(8):1409-18. doi:10.1007/s00467-009-1322-7
31. Sweigard JH, Yanai R, Gaissert P, Saint-Geniez M, Kataoka K, Thanos A, et al. The alternative complement pathway regulates pathological angiogenesis in the retina. FASEB J (2014) 28(7):3171-82. doi:10.1096/fj.14-251041
32. Muller F, Renne T. Novel roles for factor XII-driven plasma contact activation system. Curr Opin Hematol (2008) 15(5):516-21. doi:10.1097/MOH.0b013e328309ec85
33. Fujita T. Evolution of the lectin-complement pathway and its role in innate immunity. Nat Rev Immunol (2002) 2(5):346-53. doi:10.1038/nri800
34. Schwaeble W, Dahl MR, Thiel S, Stover C, Jensenius JC. The mannan-binding lectin-associated serine proteases (MASPs) and MAp19: four components of the lectin pathway activation complex encoded by two genes. Immunobiology (2002) 205(4-5):455-66. doi:10.1078/0171-2985-00146
35. Matsushita M, Fujita T. The lectin pathway. Res Immunol (1996) 147(2):115-8. doi:10.1016/0923-2494(96)87185-9
36. Wallis R, Mitchell DA, Schmid R, Schwaeble WJ, Keeble AH. Paths reunited: initiation of the classical and lectin pathways of complement activation. Immunobiology (2010) 215(1):1-11. doi:10.1016/j.imbio.2009.08.006
37. Cooper NR. The classical complement pathway: activation and regulation of the first complement component. Adv Immunol (1985) 37:151-216.
38. Ali YM, Kenawy HI, Muhammad A, Sim RB, Andrew PW, Schwaeble WJ. Human L-ficolin, a recognition molecule of the lectin activation pathway of complement, activates complement by binding to pneumolysin, the major toxin of Streptococcus pneumoniae. PLoS One (2013) 8(12):e82583. doi:10.1371/journal.pone.0082583
39. Ali YM, Lynch NJ, Haleem KS, Fujita T, Endo Y, Hansen S, et al. The lectin pathway of complement activation is a critical component of the innate immune response to pneumococcal infection. PLoS Pathog (2012) 8(7):e1002793. doi:10.1371/journal.ppat.1002793
40. Nilsson B, Nilsson Ekdahl K. The tick-over theory revisited: is C3 a contact-activated protein? Immunobiology (2012) 217(11):1106-10. doi:10.1016/j.imbio.2012.07.008
41. Lachmann PJ. The amplification loop of the complement pathways. In:Alt FW, Advances in Immunology. Amsterdam: Elsevier Inc (2009). p. 115-49. doi:10.1016/S0065-2776(08)04004-2
42. Walport MJ. Complement. First of two parts. N Engl J Med (2001) 344(14):1058-66. doi:10.1056/NEJM200104053441406
43. Walport MJ. Complement. Second of two parts. N Engl J Med (2001) 344(15):1140-4. doi:10.1056/NEJM200104123441506
44. Xu Y, Narayana SV, Volanakis JE. Structural biology of the alternative pathway convertase. Immunol Rev (2001) 180:123-35. doi:10.1034/j.1600-065X.2001.1800111.x
45. Kemper C, Hourcade DE. Properdin: new roles in pattern recognition and target clearance. Mol Immunol (2008) 45(16):4048-56. doi:10.1016/j.molimm.2008.06.034
46. Fearon DT, Austen KF. Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase. J Exp Med (1975) 142(4):856-63.
47. Wang Y, Bjes ES, Esser AF. Molecular aspects of complement-mediated bacterial killing. Periplasmic conversion of C9 from a protoxin to a toxin. J Biol Chem (2000) 275(7):4687-92. doi:10.1074/jbc.275.7.4687
48. Podack ER, Muller-Eberhard HJ, Horst H, Hoppe W. Membrane attach complex of complement (MAC): three-dimensional analysis of MAC-phospholipid vesicle recombinants. J Immunol (1982) 128(5):2353-7.
49. Davie E, Ratnoff O. Waterfall sequence for intrinsic blood clotting. Science (1964) 145(3638):1310-2. doi:10.1126/science.145.3638.1310
50. MacFarlane R. An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. Nature (1964) 202:498-9. doi:10.1038/202498a0
51. Mann KG, Krishnaswamy S, Lawson JH. Surface-dependent hemostasis. Semin Hematol (1992) 29(3):213-26.
52. Hoffman M. A cell-based model of coagulation and the role of factor VIIa. Blood Rev (2003) 17(Suppl 1):S1-5. doi:10.1016/S0268-960X(03)90000-2
53. Morrissey JH. Plasma factor VIIa: measurement and potential clinical significance. Haemostasis (1996) 26(Suppl 1):66-71.
54. Morrissey JH, Tajkhorshid E, Sligar SG, Rienstra CM. Tissue factor/factor VIIa complex: role of the membrane surface. Thromb Res (2012) 129(Suppl 2):S8-10. doi:10.1016/j.thromres.2012.02.019
55. Wildgoose P, Nemerson Y, Hansen LL, Nielsen FE, Glazer S, Hedner U. Measurement of basal levels of factor VIIa in hemophilia A and B patients. Blood (1992) 80(1):25-8.
56. McMichael M. New models of hemostasis. Top Companion Anim Med (2012) 27(2):40-5. doi:10.1053/j.tcam.2012.07.005
57. Giesen PL, Rauch U, Bohrmann B, Kling D, Roqué M, Fallon JT, et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci U S A (1999) 96(5):2311-5. doi:10.1073/pnas.96.5.2311
58. Zillmann A, Luther T, Müller I, Kotzsch M, Spannagl M, Kauke T, et al. Platelet-associated tissue factor contributes to the collagen-triggered activation of blood coagulation. Biochem Biophys Res Commun (2001) 281(2):603-9. doi:10.1006/bbrc.2001.4399
59. Müller I, Klocke A, Alex M, Kotzsch M, Luther T, Morgenstern E, et al. Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets. FASEB J (2003) 17(3):476-8. doi:10.1096/fj.02-0574fje
60. Maugeri N, Brambilla M, Camera M, Carbone A, Tremoli E, Donati MB, et al. Human polymorphonuclear leukocytes produce and express functional tissue factor upon stimulation. J Thromb Haemost (2006) 4(6):1323-30. doi:10.1111/j.1538-7836.2006.01968.x
61. Moosbauer C, Morgenstern E, Cuvelier SL, Manukyan D, Bidzhekov K, Albrecht S, et al. Eosinophils are a major intravascular location for tissue factor storage and exposure. Blood (2007) 109(3):995-1002. doi:10.1182/blood-2006-02-004945
62. Darbousset R, Thomas GM, Mezouar S, Frère C, Bonier R, Mackman N, et al. Tissue factor-positive neutrophils bind to injured endothelial wall and initiate thrombus formation. Blood (2012) 120(10):2133-43. doi:10.1182/blood-2012-06-437772
63. Reinhardt C, von Brühl ML, Manukyan D, Grahl L, Lorenz M, Altmann B, et al. Protein disulfide isomerase acts as an injury response signal that enhances fibrin generation via tissue factor activation. J Clin Invest (2008) 118(3):1110-22. doi:10.1172/JCI32376
64. Cho J, Furie BC, Coughlin SR, Furie B. A critical role for extracellular protein disulfide isomerase during thrombus formation in mice. J Clin Invest (2008) 118(3):1123-31. doi:10.1172/JCI34134
65. Jasuja R, Passam FH, Kennedy DR, Kim SH, van Hessem L, Lin L, et al. Protein disulfide isomerase inhibitors constitute a new class of antithrombotic agents. J Clin Invest (2012) 122(6):2104-13. doi:10.1172/JCI61228
66. Rivers RP, Hathaway WE, Weston WL. The endotoxin-induced coagulant activity of human monocytes. Br J Haematol (1975) 30(3):311-6. doi:10.1111/j.1365-2141.1975.tb00547.x
67. Smith SA. The cell-based model of coagulation. J Vet Emerg Crit Care (San Antonio) (2009) 19(1):3-10. doi:10.1111/j.1476-4431.2009.00389.x
68. Revak SD, Cochrane CG, Griffin JH. The binding and cleavage characteristics of human Hageman factor during contact activation. A comparison of normal plasma with plasmas deficient in factor XI, prekallikrein, or high molecular weight kininogen. J Clin Invest (1977) 59(6):1167-75. doi:10.1172/JCI108741
69. Smith SA, Choi SH, Davis-Harrison R, Huyck J, Boettcher J, Rienstra CM, et al. Polyphosphate exerts differential effects on blood clotting, depending on polymer size. Blood (2010) 116(20):4353-9. doi:10.1182/blood-2010-01-266791
70. Smith SA, Mutch NJ, Baskar D, Rohloff P, Docampo R, Morrissey JH. Polyphosphate modulates blood coagulation and fibrinolysis. Proc Natl Acad Sci U S A (2006) 103(4):903-8. doi:10.1073/pnas.0507195103
71. Renne T, Schmaier AH, Nickel KF, Blomback M, Maas C. In vivo roles of factor XII. Blood (2012) 120(22):4296-303. doi:10.1182/blood-2012-07-292094
72. Kannemeier C, Shibamiya A, Nakazawa F, Trusheim H, Ruppert C, Markart P, et al. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci U S A (2007) 104(15):6388-93. doi:10.1073/pnas.0608647104
73. Oehmcke S, Morgelin M, Herwald H. Activation of the human contact system on neutrophil extracellular traps. J Innate Immun (2009) 1(3):225-30. doi:10.1159/000203700
74. Kunapuli SP, DeLa Cadena RA, Colman RW. Deletion mutagenesis of high molecular weight kininogen light chain. Identification of two anionic surface binding subdomains. J Biol Chem (1993) 268(4):2486-92.
75. Siebeck M, Cheronis JC, Fink E, Kohl J, Spies B, Spannagl M, et al. Dextran sulfate activates contact system and mediates arterial hypotension via B2 kinin receptors. J Appl Physiol (1985) (1994) 77(6):2675-80.
76. Naito K, Fujikawa K. Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. J Biol Chem (1991) 266(12):7353-8.
77. Kishimoto TK, Viswanathan K, Ganguly T, Elankumaran S, Smith S, Pelzer K, et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med (2008) 358(23):2457-67. doi:10.1056/NEJMoa0803200
78. Scott CF, Colman RW. Fibrinogen blocks the autoactivation and thrombin-mediated activation of factor XI on dextran sulfate. Proc Natl Acad Sci U S A (1992) 89(23):11189-93. doi:10.1073/pnas.89.23.11189
79. Smith SA. Overview of hemostasis. In: Weiss D, Wardrop J, editors. Schlam's Veterinary Hematology. Philadelphia, PA: Lippincott Williams and Wilkins (2011). p. 635-53.
80. Oehmcke S, Herwald H. Contact system activation in severe infectious diseases. J Mol Med (Berl) (2010) 88(2):121-6. doi:10.1007/s00109-009-0564-y
81. Emsley J, McEwan PA, Gailani D. Structure and function of factor XI. Blood (2010) 115(13):2569-77. doi:10.1182/blood-2009-09-199182
82. Renné T, Pozgajová M, Grüner S, Schuh K, Pauer HU, Burfeind P, et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med (2005) 202(2):271-81. doi:10.1084/jem.20050664
83. Gailani D, Renne T. The intrinsic pathway of coagulation: a target for treating thromboembolic disease? J Thromb Haemost (2007) 5(6):1106-12. doi:10.1111/j.1538-7836.2007.02446.x
84. Salomon O, Steinberg DM, Koren-Morag N, Tanne D, Seligsohn U. Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. Blood (2008) 111(8):4113-7. doi:10.1182/blood-2007-10-120139
85. Van Der Meijden PE, Van Schilfgaarde M, Van Oerle R, Renne T, ten Cate H, Spronk HM. Platelet-and erythrocyte-derived microparticles trigger thrombin generation via factor XIIa. J Thromb Haemost (2012) 10(7):1355-62. doi:10.1111/j.1538-7836.2012.04758.x
86. Lu G, Broze GJ Jr, Krishnaswamy S. Formation of factors IXa and Xa by the extrinsic pathway: differential regulation by tissue factor pathway inhibitor and antithrombin III. J Biol Chem (2004) 279(17):17241-9. doi:10.1074/jbc. M312827200
87. Baugh RJ, Broze GJ Jr, Krishnaswamy S. Regulation of extrinsic pathway factor Xa formation by tissue factor pathway inhibitor. J Biol Chem (1998) 273(8):4378-86. doi:10.1074/jbc.273.8.4378
88. Osterud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci U S A (1977) 74(12):5260-4. doi:10.1073/pnas.74.12.5260
89. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med (2008) 359(9):938-49. doi:10.1056/NEJMra0801082
90. Choi SH, Smith SA, Morrissey JH. Polyphosphate is a cofactor for the activation of factor XI by thrombin. Blood (2011) 118(26):6963-70. doi:10.1182/blood-2011-07-368811
91. Davis AE III. Biological effects of C1 inhibitor. Drug News Perspect (2004) 17(7):439-46. doi:10.1358/dnp.2004.17.7.863703
92. Amara U, Rittirsch D, Flierl M, Bruckner U, Klos A, Gebhard F, et al. Interaction between the coagulation and complement system. Adv Exp Med Biol (2008) 632:71-9.
93. Ganter MT, Brohi K, Cohen MJ, Shaffer LA, Walsh MC, Stahl GL, et al. Role of the alternative pathway in the early complement activation following major trauma. Shock (2007) 28(1):29-34. doi:10.1097/shk.0b013e3180342439
94. Hecke F, Schmidt U, Kola A, Bautsch W, Klos A, Kohl J. Circulating complement proteins in multiple trauma patients-correlation with injury severity, development of sepsis, and outcome. Crit Care Med (1997) 25(12):2015-24. doi:10.1097/00003246-199712000-00019
95. Peerschke EI, Yin W, Grigg SE, Ghebrehiwet B. Blood platelets activate the classical pathway of human complement. J Thromb Haemost (2006) 4(9):2035-42. doi:10.1111/j.1538-7836.2006.02065.x
96. 2O). J Immunol (2013) 190(12):6457-67. doi:10.4049/jimmunol.1300610
97. Del Conde I, Cruz MA, Zhang H, Lopez JA, Afshar-Kharghan V. Platelet activation leads to activation and propagation of the complement system. J Exp Med (2005) 201(6):871-9. doi:10.1084/jem.20041497
98. Huber-Lang M, Sarma JV, Zetoune FS, Rittirsch D, Neff TA, McGuire SR, et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med (2006) 12(6):682-7. doi:10.1038/nm1419
99. Amara U, Flierl MA, Rittirsch D, Klos A, Chen H, Acker B, et al. Molecular intercommunication between the complement and coagulation systems. J Immunol (2010) 185(9):5628-36. doi:10.4049/jimmunol.0903678
100. Schaiff WT, Eisenberg PR. Direct induction of complement activation by pharmacologic activation of plasminogen. Coron Artery Dis (1997) 8(1):9-18. doi:10.1097/00019501-199701000-00002
101. Ghebrehiwet B, Silverberg M, Kaplan AP. Activation of the classical pathway of complement by Hageman factor fragment. J Exp Med (1981) 153(3):665-76. doi:10.1084/jem.153.3.665
102. Wiggins RC, Giclas PC, Henson PM. Chemotactic activity generated from the fifth component of complement by plasma kallikrein of the rabbit. J Exp Med (1981) 153(6):1391-404. doi:10.1084/jem.153.6.1391
103. DiScipio RG. The activation of the alternative pathway C3 convertase by human plasma kallikrein. Immunology (1982) 45(3):587-95.
104. Krarup A, Wallis R, Presanis JS, Gal P, Sim RB. Simultaneous activation of complement and coagulation by MBL-associated serine protease 2. PLoS One (2007) 2(7):e623. doi:10.1371/journal.pone.0000623
105. Wiedmer T, Esmon CT, Sims PJ. Complement proteins C5b-9 stimulate procoagulant activity through platelet prothrombinase. Blood (1986) 68(4):875-80.
106. Tedesco F, Pausa M, Nardon E, Introna M, Mantovani A, Dobrina A. The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity. J Exp Med (1997) 185(9):1619-27. doi:10.1084/jem.185.9.1619
107. Ikeda K, Nagasawa K, Horiuchi T, Tsuru T, Nishizaka H, Niho Y. C5a induces tissue factor activity on endothelial cells. Thromb Haemost (1997) 77(2):394-8.
108. Ritis K, Doumas M, Mastellos D, Micheli A, Giaglis S, Magotti P, et al. A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol (2006) 177(7):4794-802. doi:10.4049/jimmunol.177.7.4794
109. Wojta J, Kaun C, Zorn G, Ghannadan M, Hauswirth AW, Sperr WR, et al. C5a stimulates production of plasminogen activator inhibitor-1 in human mast cells and basophils. Blood (2002) 100(2):517-23. doi:10.1182/blood. V100.2.517
110. Ham TH. Chronic hemolytic anemia with paroxysmal nocturnal hemoglobinuria. A study of the mechanism of hemolysis in relation to acid-base equilibrium. N Engl J Med (1937) 217:215-7. doi:10.1056/NEJM193712022172307
111. Hinz CF Jr, Jordan WS Jr, Pillemer L. The properdin system and immunity. IV. The hemolysis of erythrocytes from patients with paroxysmal nocturnal hemoglobinuria. J Clin Invest (1956) 35(5):453-7. doi:10.1172/JCI103296
112. Hammond DJ Jr, Singh SK, Thompson JA, Beeler BW, Rusiñol AE, Pangburn MK, et al. Identification of acidic pH-dependent ligands of pentameric C-reactive protein. J Biol Chem (2010) 285(46):36235-44. doi:10.1074/jbc. M110.142026
113. Hecke F, Hoehn T, Strauss E, Obladen M, Sonntag J. In-vitro activation of complement system by lactic acidosis in newborn and adults. Mediators Inflamm (2001) 10(1):27-31. doi:10.1080/09629350123788
114. Renaux JL, Thomas M, Crost T, Loughraieb N, Vantard G. Activation of the kallikrein-kinin system in hemodialysis: role of membrane electronegativity, blood dilution, and pH. Kidney Int (1999) 55(3):1097-103. doi:10.1046/j.1523-1755.1999.0550031097.x
115. Thomas M, Valette P, Mausset AL, Dejardin P. High molecular weight kininogen adsorption on hemodialysis membranes: influence of pH and relationship with contact phase activation of blood plasma. Influence of pre-treatment with poly(ethyleneimine). Int J Artif Organs (2000) 23(1):20-6.
116. Buerke M, Murohara T, Lefer AM. Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion. Circulation (1995) 91(2):393-402. doi:10.1161/01.CIR.91.2.393
117. Heideman M, Hugli TE. Anaphylatoxin generation in multisystem organ failure. J Trauma (1984) 24(12):1038-43. doi:10.1097/00005373-198412000-00006
118. Jones AL, Hulett MD, Parish CR. Histidine-rich glycoprotein: a novel adaptor protein in plasma that modulates the immune, vascular and coagulation systems. Immunol Cell Biol (2005) 83(2):106-18. doi:10.1111/j.1440-1711.2005.01320.x
119. Gorgani NN, Parish CR, Easterbrook Smith SB, Altin JG. Histidine-rich glycoprotein binds to human IgG and C1q and inhibits the formation of insoluble immune complexes. Biochemistry (1997) 36(22):6653-62. doi:10.1021/bi962573n